Do Emerging HFpEF Treatments Work? The Role of Non-disease Modifying Treatments including SGLT2i, MRAs, GLP1s, and implantable hemodynamic monitors in Cardiac Amyloidosis.
Cuddy, Sarah
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Griffin, Jan
( Medical University of South Carolina
, Charleston
, South Carolina
, United States
)
Author Disclosures:
Sarah Cuddy:DO have relevant financial relationships
;
Consultant:bridgebio:Active (exists now)
; Consultant:attralus:Active (exists now)
; Research Funding (PI or named investigator):NIH:Active (exists now)
; Research Funding (PI or named investigator):aha:Active (exists now)
; Consultant:intellia:Past (completed)
; Research Funding (PI or named investigator):intellia:Active (exists now)
; Research Funding (PI or named investigator):alnylam:Active (exists now)
; Research Funding (PI or named investigator):alexion:Active (exists now)
; Research Funding (PI or named investigator):astrazenca:Active (exists now)
; Speaker:pfizer:Past (completed)
; Advisor:pfizer:Past (completed)
; Advisor:novo nordisk:Active (exists now)
; Advisor:astrazeneca:Active (exists now)
; Speaker:bridgebio:Past (completed)
; Speaker:novo nordisk:Past (completed)
| Jan Griffin:No Answer